


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
POSITIVE RESULTS FROM PHASE II TRIAL OF TQA3605 “CORE PROTEIN
ALLOSTERIC MODULATOR” FOR CHRONIC HEPATITIS B

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the national Class I innovative drug, TQA3605 tablets “Core Protein Allosteric Modulator (CpAM)” independently developed by the Group, has recently completed Phase II clinical trials for patients with chronic hepatitis B virus (HBV) infection and met the primary endpoint.

The study is a randomized, double-blind, placebo-controlled, multi-center phase II trial (NCT06644417) designed to evaluate the efficacy and safety of TQA3605 in combination with nucleos(t)ide analogues (NAs) in treated chronic HBV-infected subjects with low-level viremia. A total of 122 subjects were enrolled in the study and allocated to a placebo-controlled group and several TQA3605 dose groups, with once-daily oral administration regimen.

The study results demonstrated that among HBV-infected adults who had received NAs treatment for at least 12 months, combining TQA3605 with NAs for 24-week significantly increased the proportion of subjects achieving HBV DNA levels below the lower limit of quantification (<20 IU/mL). All TQA3605 dose groups reached approximately 90%, significantly outperforming the NAs monotherapy control group ($p < 0.0001$). In terms of safety, TQA3605 demonstrated a generally favourable safety profile. The overall incidence of adverse reactions was comparable to the control group, with most treatment-emergent adverse events (TEAEs) being Grade 1 to 2. No new safety signals were observed. Detailed results from the study will be presented at subsequent international academic conferences.

Currently, there are approximately 86 million HBV carriers in the PRC, among whom around 30 million are chronic HBV-infected patients. However, the diagnosis rate and treatment rate stand at merely 18.7% and 11% respectively. Over 80% of hepatocellular carcinoma (HCC) cases are attributable to chronic HBV infection. Although NAs can effectively suppress viral replication and delay cirrhosis progression in most patients, certain patients are found to be non-responders or partial responders. Moreover, HBV-infected patients require long-term medication and face the risk of viral rebound upon dose discontinuation, thus underscoring the urgent need for novel therapeutic solutions.

TQA3605 is a CpAM for HBV independently developed by the Group. It can effectively suppress multiple HBV genotypes and exhibits no cross-resistance with NAs. Currently, no CpAM targeting HBV has been approved for marketing in the world. Compared to other similar investigational drugs, TQA3605 demonstrates a more favourable safety profile. Its once-daily oral administration regimen also offers greater convenience, positioning it as a promising new treatment option for patients with chronic HBV infection.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 27 January 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, and Mr. Tian Zhoushan, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.